Resumen de Investigación
Analyzed using Evidence Intelligence™

Canagliflozin reduces cardiovascular and kidney risks in type 2 diabetes

Powered by the Dediabetes Evidence Intelligence™ framework

Última actualización 6 de julio de 2026

Key finding

Canagliflozin reduced the risk of major adverse cardiovascular events (HR, 0.84 [95% CI, 0.76–0.94])

This study evaluated the effects of canagliflozin on cardiovascular and kidney outcomes in individuals with type 2 diabetes, finding a reduction in major adverse cardiovascular events.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Extended (5–20+ y)

Risk of bias

Some Concerns

Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.

Plain-language summary

What this paper says

A plain-language read of the study's main message and where it applies.

Study focus

This study evaluated the effects of canagliflozin on cardiovascular and kidney outcomes in individuals with type 2 diabetes, finding a reduction in major adverse cardiovascular events.

Clinical relevance

These findings are significant as they suggest that canagliflozin may be an effective option for reducing cardiovascular risks in patients with type 2 diabetes, a population that is already at high risk for heart disease. Understanding the benefits of this medication can help healthcare providers make informed treatment decisions to improve patient outcomes.

Keep in mind

Effectiveness of canagliflozin for other outcomes remains unclear. Study results may not be generalizable to all populations with type 2 diabetes. Limited information on long-term effects of canagliflozin.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Abhinav S, Amir R, Abdulaziz J, et al. Canagliflozin and Cardiovascular and Kidney Outcomes in Type 2 Diabetes. Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease. 2024;13(3):e031586. doi:10.1161/JAHA.123.031586

View DOIView on PubMedView on PMC

Efectos Principales

Canagliflozin reduced the risk of composite cardiovascular events (HR, 0.84 [95% CI, 0.76–0.94]).

No treatment effect heterogeneity was observed for hospitalization for heart failure.

No treatment effect heterogeneity was observed for cardiovascular death.

No treatment effect heterogeneity was observed for end-stage kidney disease.

No treatment effect heterogeneity was observed for all-cause mortality.

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Canagliflozin and All-cause mortality, Cardiovascular death, Composite cardiovascular events (CV death, MI, stroke, HF hospitalization), and 2 more.

This study contributes evidence to

Intervention

Canagliflozin

Outcome

All-cause mortality

Evidence topic

Cardiovascular Risk

Primary intervention

Canagliflozin

Primary outcomes

  • All-cause mortality
  • Cardiovascular death
  • Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence topics

Cardiovascular RiskSGLT2 Inhibitors

Primary intervention

Canagliflozin

Primary outcomes

All-cause mortalityCardiovascular deathComposite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

5
Evidence pairs
5
Relationships
2
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 64

2

Related topics

5

Evidence pairs

58

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 5 evidence relationships
  • Includes primary outcome data
  • Linked to 2 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Relación de evidencia

SGLT2 Inhibitors and Cardiovascular Outcomes

Evidencia relacionada

Relación de evidencia

SGLT2 Inhibitors and Kidney Function

Seguir evidencia

Tema de evidencia

Cardiovascular Risk

Seguir evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

All-cause mortality

Canagliflozin → All-cause mortality

Canagliflozin → All-cause mortality

Evidence Intelligence™
ImpactScore™
100
Very Positive
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Cardiovascular death

Canagliflozin → Cardiovascular death

Canagliflozin → Cardiovascular death

Evidence Intelligence™
ImpactScore™
100
Very Positive
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Hospitalization for heart failure

Canagliflozin → Hospitalization for heart failure

Canagliflozin → Hospitalization for heart failure

Evidence Intelligence™
ImpactScore™
100
Very Positive
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Nephropathy progression

Canagliflozin → Nephropathy progression

Canagliflozin → Nephropathy progression

Evidence Intelligence™
ImpactScore™
100
Very Positive
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ConsistencyScore™
unclear
Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence Tracker

Build your personal Evidence Workspace

Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.

Today's Activity

Your Evidence Workspace

Free account

Saved this study

Your free account becomes your personal diabetes evidence workspace.

Evidence Tracker

12 tracked topics

Saved Studies

48 studies

Research Notes

Coming Soon

Weekly Evidence Digest

Coming Soon

evidence suggest

La Evidencia Sugiere

  • Canagliflozin reduced major adverse cardiovascular events by 16%.
  • No significant treatment effects were observed for heart failure or mortality.
  • Study included diverse participants with type 2 diabetes.
who this applies

A quién se aplica

  • Adults diagnosed with type 2 diabetes.
  • Individuals at high risk for cardiovascular events.
keep in mind

Tener en Cuenta

  • Results may not apply to younger populations or those without diabetes.
  • Further research is needed to explore long-term effects.
  • The study did not assess the impact of canagliflozin on quality of life.
between the lines

Entre Líneas

  • Effectiveness of canagliflozin for other outcomes remains unclear.
  • Study results may not be generalizable to all populations with type 2 diabetes.
  • Limited information on long-term effects of canagliflozin.

Save this study

Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.

Today's Activity

Your Evidence Workspace

Free account

Saved this study

Your free account becomes your personal diabetes evidence workspace.

Evidence Tracker

12 tracked topics

Saved Studies

48 studies

Research Notes

Coming Soon

Weekly Evidence Digest

Coming Soon

Already have an account?

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Powered by the Dediabetes Evidence Intelligence™ framework

This study contributes to evidence on SGLT2 Inhibitors and Cardiovascular Outcomes, SGLT2 Inhibitors and Cardiovascular death.

Relaciones de evidencia relacionadas

Explore in Evidence Archive

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does SGLT2 Inhibitors improve cardiovascular outcomes?

Strong Evidence

SGLT2 Inhibitors may improve Cardiovascular Outcomes.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

  1. 1

    All-cause mortality

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

  2. 2

    Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

  3. 3

    Hospitalization for heart failure

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 5 supporting studies with generally consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
5 supporting studiesUpdated: Jul 2026
View Full Evidence

Does SGLT2 Inhibitors improve kidney function?

Strong Evidence

SGLT2 Inhibitors may improve Kidney Function.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Nephropathy progression

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 6 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
6 supporting studiesUpdated: Jul 2026
View Full Evidence

Does Canagliflozin improve cardiovascular death?

Emerging Evidence

Canagliflozin appears to improve Cardiovascular death.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Cardiovascular death

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting studyUpdated: Jul 2026
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, archive views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Cardiovascular Risk Evidence HubSGLT2 Inhibitors Evidence Hub

Explore in archive

Open broader archive views for this relationship.

All studies on Canagliflozin and All-cause mortalityAll studies on Canagliflozin and Cardiovascular deathAll studies on Canagliflozin and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)All studies on Canagliflozin and Hospitalization for heart failure

Related research

Read related research summaries.

Canagliflozin may reduce myocardial fibrosis in high-risk type 2 diabetesHbA1c mediates cardiovascular benefits of GLP-1 receptor agonistsSemaglutide improves cardiorenal outcomes in high-risk diabetes patientsIntensive glycemic control may lower cardiovascular events in some diabetes patientsCanagliflozin with metformin reduces cardiovascular risk in T2DM

No ads. No tracking.

Focused on evidence, not advertising.

Secure & private

Your data is always protected.

Always up to date

New studies added every day.